Purpose The optimal therapeutic sequence of the adjuvant chemotherapy component of
preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is …

PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation
through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell…

Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor
progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong …

The majority of lung cancer patients progressing from conventional therapies are refractory
to PD ‐L1/ PD ‐1 blockade monotherapy. Here, we show that baseline systemic CD 4 …

Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (…

Purpose: Total neoadjuvant treatment (TNT) is a valid strategy for patients with high-risk
locally advanced rectal cancer (LARC). Biomarkers of response to TNT are an unmet clinical …

Introduction We evaluate the impact of COVID‐epidemic in colorectal cancer (CRC) diagnosis
during Spain's state of emergency. Methods We compared newly diagnosed patients with …

PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …

Background. The need for preoperative chemoradiation or short-course radiation in all T3
rectal tumors is a controversial issue. A multicenter phase II trial was undertaken to evaluate …